Get the Stockscreener App
2.53
7.99%
-0.22
Pyxis Oncology Inc stock is traded at $2.53, with a volume of 197.86K.
It is down -7.99% in the last 24 hours and up +48.83% over the past month.
Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.
See More
Previous Close:
$2.75
Open:
$2.74
24h Volume:
197.86K
Relative Volume:
0.48
Market Cap:
$159.02M
Revenue:
$13.86M
Net Income/Loss:
$-79.62M
P/E Ratio:
-1.9712
EPS:
-1.2835
Net Cash Flow:
$-63.51M
1W Performance:
+38.26%
1M Performance:
+48.83%
6M Performance:
-42.10%
1Y Performance:
+120.01%
1-Day Range:
$2.525
$2.78
1-Week Range:
$1.82
$2.92
52-Week Range:
$0.97
$5.55
Pyxis Oncology Inc Stock (PYXS) Company Profile
Name
Pyxis Oncology Inc
Sector
Industry
Phone
(617) 221-9059
Address
321 HARRISON AVENUE, BOSTON
Compare PYXS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PYXS
Pyxis Oncology Inc
|
2.53 | 172.85M | 13.86M | -79.62M | -63.51M | -1.2835 |
VRTX
Vertex Pharmaceuticals Inc
|
452.30 | 110.45B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
719.68 | 74.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
824.04 | 50.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.18 | 38.03B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.64 | 32.24B | 5.36B | 287.73M | 924.18M | 2.5229 |
Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-03-25 | Resumed | Stifel | Buy |
| Sep-04-25 | Initiated | Guggenheim | Buy |
| Nov-21-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-08-24 | Initiated | Stephens | Overweight |
| Aug-08-24 | Initiated | Stifel | Buy |
| May-07-24 | Resumed | Jefferies | Buy |
| Feb-09-24 | Initiated | BTIG Research | Buy |
| Jan-23-24 | Initiated | Leerink Partners | Outperform |
| Sep-05-23 | Initiated | RBC Capital Mkts | Outperform |
| Nov-02-21 | Initiated | BofA Securities | Neutral |
| Nov-02-21 | Initiated | Credit Suisse | Outperform |
| Nov-02-21 | Initiated | Jefferies | Buy |
View All
Pyxis Oncology Inc Stock (PYXS) Latest News
Pyxis Oncology Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
TradingKey - TradingKey
Pyxis brings in former ImmunoGen dealmaker to advance MICVO - Stock Titan
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer - Weekly Voice
Wedbush Initiates Pyxis Oncology at Outperform With $6 Price Target - marketscreener.com
Wedbush initiated coverage on Pyxis Oncology with a new price target - Quantisnow
Wedbush Initiates Pyxis Oncology(PYXS.US) With Buy Rating, Announces Target Price $6 - Moomoo
Wedbush initiates coverage of Pyxis Oncology (PYXS) with outperform recommendation - MSN
Pyxis Oncology (PYXS) Price Target Increased by 13.33% to 6.94 - MSN
Short Interest in Pyxis Oncology, Inc. (NASDAQ:PYXS) Drops By 14.7% - MarketBeat
Pyxis Oncology, Inc. Files Amended 8-K/A Report for 2026 with SEC – Company Details, Address, and Nasdaq Listing - Minichart
Pyxis Oncology (PYXS) Management Strategy | Pyxis Oncology posts 15.6% EPS beat, no revenueDebt Analysis - newser.com
[ARS] Pyxis Oncology, Inc. SEC Filing - Stock Titan
Pyxis Oncology | DEFA14A: Others - Moomoo
Pyxis Oncology (NASDAQ: PYXS) details 2026 vote on directors and auditor - Stock Titan
Pyxis Oncology | 8-K/A: Current report (Amendment) - Moomoo
Lara Sullivan exit package at Pyxis Oncology (NASDAQ: PYXS) - Stock Titan
PYXS Pyxis Oncology beats Q4 2025 loss estimates, but shares shed 2.35 percent amid weak investor reaction.EBIT Margin - Newser
Pyxis Oncology (PYXS) Rating Reiterated as Buy by HC Wainwright & Co. | PYXS Stock News - GuruFocus
PYXS Pyxis Oncology Q4 2025 narrower than expected per share loss sparks double digit share price jump today.Weakness Phase - newser.com
PYXS Stock: Analyzing Pyxis Oncology's Market Performance - Bitget
Pyxis Oncology (PYXS) Cantor Global Healthcare Conference 2025 Summary - Quartr
Pyxis Oncology (PYXS) Morgan Stanley 22nd Annual Global Healthcare Conference summary - Quartr
Pyxis Oncology (PYXS) Registration Filing Summary - Quartr
Pyxis Oncology (PYXS) H.C. Wainwright 26th Annual Global Investment Conference summary - Quartr
Pyxis Oncology (PYXS) Proxy Filing Summary - Quartr
Pyxis Oncology (PYXS) Leerink Global Healthcare Conference 2025 Summary - Quartr
Stifel Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Pyxis presents preclinical data on MICVO in head and neck cancer - Investing.com India
Pyxis presents preclinical data on MICVO in head and neck cancer By Investing.com - Investing.com South Africa
Pyxis Oncology to Present New Preclinical Data Showing - GlobeNewswire
Pyxis Oncology (NASDAQ:PYXS) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
PYXS | Pyxis Oncology, Inc. Common Insider Trading - Quiver Quantitative
Growth Value: Will Pyxis Oncology Inc stock benefit from M ARate Cut & Weekly Stock Breakout Alerts - baoquankhu1.vn
Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
PYXS Stock Price, Quote & Chart | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Stock Recap: Can Pyxis Oncology Inc benefit from deglobalization2026 Earnings & Verified Chart Pattern Signals - baoquankhu1.vn
Price Action: Is Pyxis Oncology Inc part of any major index2026 Reactions & Low Drawdown Momentum Ideas - baoquankhu1.vn
Is Pyxis Oncology (PYXS) Stock overvalued relative to peers | Price at $1.46, Up 0.69%Community Buy Alerts - newser.com
Trade Report: Can Pyxis Oncology Inc expand its profit marginsCPI Data & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Is Pyxis Oncology (PYXS) Stock a Buy Now | Price at $1.45, Down 2.03%Community Momentum Stocks - newser.com
Wall Street Zen Downgrades Pyxis Oncology (NASDAQ:PYXS) to Sell - MarketBeat
PYXS Technical Analysis & Stock Price Forecast - Intellectia AI
PYXS SEC FilingsPyxis Oncology, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
PYXS Earnings History & Surprises | EPS & Revenue Results | PYXIS ONCOLOGY INC (NASDAQ:PYXS) - ChartMill
Pyxis Oncology Inc. (PYXS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Pyxis Oncology (PYXS) Receives a Rating Update from a Top Analyst - The Globe and Mail
Pyxis Oncology (NASDAQ:PYXS) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
HC Wainwright Raises Earnings Estimates for Pyxis Oncology - Defense World
Stock Report: Can Pyxis Oncology Inc expand its profit marginsDividend Hike & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Q1 EPS Estimates for Pyxis Oncology Raised by HC Wainwright - MarketBeat
Pyxis Oncology Inc Stock (PYXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.76%
1.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):